Search

根据我们的回顾性研究，在慢性淋巴细胞白血病 (CLL) 患者开始接受伊鲁替尼治疗后，应密切监测其血压，并持续数月。

… Wednesday, January 8, 2020 根据我们本月发表在《美国医学会杂志网络公开》 (JAMA Network Open) 上的回顾性研究，在慢性淋巴细胞白血病 (CLL) 患者开始接受伊鲁替尼治疗后，应密切监测其血压，持续数月。 高血压是临床试验中接受伊鲁替尼治疗的 CLL 患者发生的常见不良事件。我们在非临床试验环境中研究了 CLL 患者中与伊鲁替尼相关的高血压的发展模式、管理策略和长期血管影响。  (1) 我们的结果显示，在接受伊鲁替尼治疗的 247 例 CLL 患者的整个队列中，包括存在和不存在高血压病史的患者，患者的血压均发生显著升高。 我们的结果显示，在接受伊鲁替尼治疗的

… Monday, March 24, 2025 Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and progress.  (1) Metastatic disease develops in about 50% of patients with surgically

Memorial Sloan Kettering Cancer Center (MSK) researchers presented the results of a randomized phase III trial at today’s press program for the European Society for Medical Oncology’s 2018 Congress in Munich, Germany. The results demonstrated that a combination of the immune checkpoint blocker avelumab (Bavencio®) and the tyrosine kinase inhibitor (TKI) axitinib (Inlyta®) can significantly improve progression-free survival (PFS) in people who have been previously untreated for advanced renal cell carcinoma (RCC).

… Sunday, October 21, 2018 Memorial Sloan Kettering Cancer Center (MSK) researchers presented the results of a randomized phase III trial at today’s press program for the European Society for Medical Oncology ’s 2018 Congress in Munich, Germany. The results demonstrated that a combination of the immune

Learn how MSK's world-class Head and Neck cancer specialists help people facing throat cancer, using the latest therapies and innovations.

… Thursday, September 4, 2025 Throat cancer is a form of head and neck cancer. It starts in the throat (known as the pharynx), which includes the tonsils, back of the tongue, voice box (larynx), and the vocal cords. Some of these areas can be seen when the mouth is wide open and others only by a camera

MSK investigators are learning how cancer cells escape from the original tumor and hide out in the body. Their goal is to prevent metastatic tumors from forming.

… Friday, December 1, 2017 Summary Investigators at Memorial Sloan Kettering are conducting research to figure out how cancer cells are able to escape from the original tumor and hide out in the body. Their ultimate goal is to find ways to prevent metastatic tumors from forming. Cancer metastasis occurs

Read about an FDA approval for immunotherapy to treat head and neck squamous cell carcinoma.

… Wednesday, October 1, 2025 People with locally advanced  head and neck squamous cell carcinoma (HNSCC) now have a new treatment option that could extend their lives with fewer side effects. The  U.S. Food and Drug Administration (FDA) has approved the immunotherapy drug  pembrolizumab (Keytruda® ) to

The June 29 edition of “MSK Science Spotlight” will feature chemical biologist Yael David, PhD, “Uncovering Epigenetic Events that Drive Oncogenesis.

… Monday, June 29, 2020 The June 29 edition of “ MSK Science Spotlight ” will feature chemical biologist Yael David, PhD, “Uncovering Epigenetic Events that Drive Oncogenesis.” A member of Sloan Kettering Institute , Dr. David develops and applies methods in chemical biology toward studying epigenetic

At Memorial Sloan Kettering Cancer Center’s 45th annual ceremony, graduating master's and PhD students were honored and award winners were recognized.

… Friday, May 17, 2024 GSK master’s degree recipients with members of the platform party GSK master’s degree recipients with members of the platform party. Back row, from left: Dr. Urvi Ajay Shah, Dr. Michael Scordo, Dr. Ioannis Politikos, Dr. Ivan Sergueivich Kotchetkov, and Dr. Vance Broach. Front row

Zeda Zhang was recently awarded the Predoctoral to Postdoctoral Fellow Transition Award from the National Cancer Institute (NCI).

… Friday, November 17, 2017 Summary Zeda Zhang was recently honored with an award from the NCI for his work addressing drug resistance in prostate cancer care. Zeda Zhang was recently awarded the Predoctoral to Postdoctoral Fellow Transition Award from the National Cancer Institute (NCI). The nationally

Genetic sequencing of prostate tumors can identify men who should receive immunotherapy drugs.

… Friday, January 11, 2019 Summary Immunotherapy drugs called checkpoint inhibitors can be very effective but don’t work for most people with prostate cancer . A small subset of men whose prostate tumors have a genetic abnormality called high microsatellite instability do respond to the drugs. Genetic